NCT05632445View on ClinicalTrials.gov

Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

June 12, 2019

Study Completion Date

October 30, 2022

Conditions
Left Atrial Appendage Occlusion
Interventions
DRUG

Apixaban vs. DAPT

Apixaban vs DAPT after LAAO

Trial Locations (1)

08036

Hospital Clinic Barcelona, Barcelona

All Listed Sponsors
lead

DR. XAVIER FREIXA

OTHER

NCT05632445 - Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA) | Biotech Hunter | Biotech Hunter